NCT02117375Completed
EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the prognostic value of early focal lesions and early diffuse lesions on ambulatory disability progression within 5 years after clinical onset.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 115 (actual)
- First submitted
- 10 Apr 2014
- Start date
- Jan 2014
- Primary completion date
- 24 Jan 2023
- Lead sponsor
- Rennes University Hospital
- Diseases
- Multiple sclerosis
- NCT number
- NCT02117375
What you commit to
- Study type: Interventional
- Participants enrolled: 115
- From Jan 2014 to the primary completion date, 24 Jan 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients treated with immunosuppressive therapy
Other
- Multiple Sclerosis progressive
- Pregnancy
- Healthy volunteers:
- -Pregnancy
Who the study is looking for
- Relapsing Remitting Multiple Sclerosis patients (Mac Donald 2010 criteria)
- First clinical event \< 1 year
- Brain MRI \> 9 lesions or/and spinal cord attack with focal lesion on spinal cord MRI
- Score Expended Disability Status Scale \< 3
- Age between 18 and 40 years
- -Age between 18 and 40 years
Criteria the registry did not label
- Patients with multiple sclerosis:
Age in the registry: 18 years to 40 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Rennes Coordinator of this site? Confirm its status | Rennes | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.